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Effect of IR laser on myoblasts: a proteomic study
Monica Monici,a Francesca Cialdai,a Francesco Ranaldi,b Paolo Paoli,b
Francesca Boscaro,c Gloriano Monetic and Anna Caselliwb
Laser therapy is used in physical medicine and rehabilitation to accelerate muscle recovery and in sports
medicine to prevent damages produced by metabolic disturbances and inflammatory reactions after
heavy exercise. The aim of this research was to get insight into possible benefits deriving from the
application of an advanced IR laser system to counteract deficits of muscle energy metabolism and
stimulate the recovery of hypotrophic tissue. We studied the effect of IR laser treatment on
proliferation, differentiation, cytoskeleton organization and global protein expression in C2C12
myoblasts. We found that laser treatment induced a decrease in the cell proliferation rate without
affecting cell viability, while leading to cytoskeletal rearrangement and expression of the early
differentiation marker MyoD. The differential proteome analysis revealed the up-regulation and/or
modulation of many proteins known to be involved in cell cycle regulation, cytoskeleton organization
and differentiation.
Introduction
Since the seventies laser therapy has been widely used in sports
medicine, physiatry and rehabilitation to treat muscle diseases
of different origins: myalgias, contusions, sprains, lacerations
and damage due to heavy exercise.1–3 These diseases have in
common the painful symptomatology, the inflammatory component
and, in the case of injuries, the need to repair the tissue portion in
which the muscle fibers have suffered damage. The application of
laser therapy, either alone or combined with other treatments,
both pharmacological and instrumental, has its rationale in the
therapeutic effects that are attributed to laser radiation: analgesic,
anti-inflammatory, anti-oedema and ability to promote wound
healing and tissue repair. A large amount of literature shows that
laser radiation can affect the cell energy metabolism and ATP
production,4,5 the response of immune cells to injury,6
the production of inflammation mediators,7–9 the behavior of
fibroblasts10–12 and endothelial cells.13,14 Moreover, laser radiation
can improve microcirculation15 and relieve pain both indirectly
through the effects mentioned above, and directly, by acting on
receptors and nerve endings.16–19
Although many clinical studies give evidence for the effective-
ness of IR laser therapy in the treatment of muscular disorders,
thus justifying the wide application of laser treatments in
clinical rehabilitation and sports medicine, in the literature
there are conflicting results1,20–27 most likely caused by differences
in the laser sources and treatment parameters that have been used.
In the last few years significant progress has been made in
understanding the mechanisms by which the IR laser therapy
promotes the healing process and recovery of muscle tissue.
Recent studies, carried out both in animal models and human
subjects, demonstrated that pre-exercise treatment with IR
laser can significantly delay muscle fatigue and accelerate
post-exercise recovery.3,28 In rats, it has been found that laser
treatment reduces the inflammatory response caused by experi-
mentally induced muscle trauma and is able to block the effects of
reactive oxygen species (ROS) release and the activation of NF-kB.29
Laser-induced changes in inflammatory biomarkers and signifi-
cant muscle recovery have been observed also in a rat model of
myopathy.30 Other authors found that, in traumatized muscle
tissues, laser therapy induces an increase in activity of the com-
plexes I, II, III and VI of the respiratory chain that may lead to an
increase in ATP synthesis and faster muscle recovery.5 A study
aimed at evaluating the effectiveness of IR laser radiation in
promoting the recovery of atrophied skeletal muscles demon-
strated that the laser treatment favours tissue repair through
activation of satellite cells and induction of neoangiogenesis.31
However, despite the fact that over the past decade numer-
ous studies have significantly improved our knowledge, in
many respects the effects of radiation emitted by different laser
sources on muscle tissue and its repair mechanisms are far to
be completely understood.
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This paper reports the results of a study aimed to investigate
the behavior of C2C12 cells exposed to the emission of a dual
wavelength IR laser. The C2C12 skeletal muscle cell line has
been derived from murine satellite cells and is widely accepted
as a model to study the behavior of satellite cells,32 which play a
crucial role in skeletal muscle regeneration and repair33 and are
capable of repopulating damaged and atrophied muscle.34 The
source chosen to perform the treatments was a synchronized IR
dual emission laser system, with wavelengths of 808 and
905 nm, respectively. Most of the recent studies reported the
effectiveness of laser emissions in the range 800–830 nm as well
as emissions around 905 nm in triggering a biological response
in muscle tissue. Sources with multiple emissions are widely
used in clinics but little is studied from the point of view of the
effects that induce in the cellular component of muscle tissue.
We considered interesting to study the effects of a source that
simultaneously emits two wavelengths which, on the basis of
the literature, both can favour the recovery of homeostasis in
diseased muscles.
The behavior of C2C12 cells was assessed before and
after exposure to laser treatments in terms of cell viability,
morphology, proliferation, differentiation and proteomic profile.
To the best of our knowledge this is the first time that the effect
of IR laser radiation on the proteomic profile of myoblasts is
being studied.
Results and discussion
Effect of MLS laser treatment on viability, proliferation and
differentiation of C2C12 cells
Murine myoblasts C2C12 were treated with a Multiwave Locked
System laser (MLS laser) as described in the experimental
section. Before proceeding to the appropriate morphological
and proteomic studies, we analyzed the effect of the laser
treatment on cell viability and proliferation. The trypan blue
assay, performed both after a single exposure to the laser
radiation and after 3 exposures carried out on consecutive days,
showed that in treated samples there were no significant
changes in cell viability (over 98%) compared to the control.
The cell count did not show significant differences after a
single exposure, whereas after 3 treatments with MLS laser,
the cell number decreased moderately (about 23.4%) with
respect to the control. Since MLS laser treatment does not
affect cell viability, we hypothesized that the reduced prolifera-
tion rate of MLS laser treated cells was caused by the triggering
of a differentiative process. To verify our hypothesis we ana-
lyzed expression and distribution of MyoD, which is widely
recognized as an early marker of myoblast differentiation. In
fact it is known that in skeletal myogenesis, gene expression is
initiated by MyoD and includes the expression of specific Mef2
isoforms and activation of the p38 mitogen-activated protein
kinase (MAPK) pathway.35 In treated cells MyoD increased
by about 26%, in comparison with controls (Fig. 1c), and
was mainly distributed in the nuclear and perinuclear area
(Fig. 1a and b). The increase in MyoD expression and the
morphological changes in the cytoskeleton structure observed
in treated cells strongly suggest that MLS laser radiation
triggered a differentiation process in C2C12 cells.
Effect of MLS laser treatment on cytoskeleton organization
The organization of the cytoskeleton network is a crucial factor
in determining cell shape, regulating cell adhesion/migration,
transducing signals and triggering intra and extracellular path-
ways. Therefore, the three major cytoskeleton components, i.e.
actin microfilaments, microtubules and intermediate filaments
were studied by immunofluorescence microscopy analysis.
Control C2C12 cells showed the expected actin distribution
(Fig. 2a): high expression in the perinuclear area, a clearly
distinguishable ‘‘actin ring’’ close to the plasma membrane
(arrow) and some stress fibers. After a cycle of three laser
treatments the ‘‘actin ring’’ delimiting each individual cell
disappeared. The cells tended to align and fuse to form tubes,
filaments running parallel to the axis of the tubes appeared
(arrows), the perinuclear area with high actin expression was
thicker (Fig. 2b). The specific staining for tubulin revealed, in
control cells, a radial distribution of the microtubules starting
from the organization centre close to the nucleus (Fig. 2c). In
treated samples a redistribution of the microtubules was
observed: they were oriented parallel to the major axis of the
cells and passed from one cell to another without interruption
(arrows) (Fig. 2d). The intermediate filaments were studied by
immunofluorescence staining of vimentin, which is their major
constituent. The analysis of protein expression and distribution
in control cells showed that the network of filaments was more
dense in the perinuclear area, where it had the shape of a ball
(Fig. 2e). In the cells treated with MLS laser, the intermediate
filaments were parallel to the longitudinal axis of the cells
(arrows), which appeared elongated and aligned to form tube-
like structures (Fig. 2f).
In summary, C2C12 cells, subjected to MLS laser treatment,
showed elongated shapes and were aligned and fused to form
structures with two or more nuclei among which were no longer
recognizable interposedmembranes (tubes). These cytoarchitectural
changes support the occurrence of a differentiation process36
since the formation of a longitudinal microtubule array is an
early event in myogenic differentiation.37 It is also known that
the reorganization of intermediate filaments and shifts from
one to the other of the two major components, vimentin and
desmin, occur during myogenesis.38–40 Remodelling of actin
Fig. 1 MyoD expression in C2C12 cells after MLS laser treatment. a: control
C2C12 cells. b: MLS treated C2C12 cells. c: quantitative expression of MyoD.
Images obtained by immunofluorescence microscopy show that, in cells treated
with MLS laser, MyoD expression increased and the transcription factor was
mainly distributed in the nuclear and perinuclear area. Image analysis revealed
that in treated cells MyoD increased by about 26%, in comparison with controls.
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microfilaments with the formation of stress fiber like structures
has a very important role leading to myofibrillogenesis and is
regulated by actin binding proteins41 and phospholipase D.42,43
Effect of MLS laser treatment on the proteome of C2C12 cells
In an attempt to identify the molecular changes induced by
laser treatment of C2C12 cells, we have studied the protein
expression pattern before and after laser treatment using 2-DE
based proteomics. To ascertain the reproducibility of results
2-DE was performed three times for each protein sample. Fig. 3
shows a representative gel image. Image analysis using Progenesis
Same Spot software allowed us to identify about 120 significantly
(Anova p value, pr 0.05) and consistently up- or down-regulated
protein spots with fold changes greater than 1.5 in terms of
average normalised volumes in both triplicate gels of two
independent experiments. Of these spots, 89 were up-regulated
and 32 down-regulated in comparison to the control cells. Fig. 3
shows the significantly regulated spots, identified by MALDI-
Tof mass spectrometry.
About eighty spots, corresponding to major protein variations,
were cut from gels, destained, digested with trypsin and
subjected to peptide mass fingerprinting followed by database
searching. MALDI-TOF MS analysis allowed the unambiguous
protein identification of 52 protein variations, corresponding to
42 proteins. Table 1 summarizes all the information obtained
by protein identification. Protein numbering corresponds to
that shown in Fig. 3. Swiss-Prot accession number and protein
name are also included. The comparison between theoretical
and measured molecular weight and pI values contributes
to confirm the MASCOT search results in most cases. The
MASCOT search results are reported in Table 1, showing
experimentally measured peptide masses matching the theoretical
ones from Swiss-Prot/UniProt entries, the percentage of the protein
sequence covered by the matching peptides (sequence coverage),
and the probabilistic score.
The identification of some protein spots, both selected as
up-regulated proteins (spot No. 7, 13–15, 17, 40) and down-
regulated ones (spot No. 4, 6, 37, 44), resulted in the same
proteins: vimentin (spot No. 4, 13–15), actin g (or b) (spot No. 17
and 44), tropomyosin a-3 chain (spot No. 6 and 40) and Rab
GDP dissociation inhibitor b (spot No. 7 and 37). The position
of these protein spots is clearly different. Fig. 4 shows details of
the two-dimensional reference maps. Both tropomyosin a-3
chain and Rab GDP dissociation inhibitor b are associated with
two spots with equal molecular weight but different isoelectric
points. The observed shift in positions of these proteins could
represent splice variants and/or post-translational modifica-
tions (i.e. phosphorylation) rather than an increase or decrease
in the absolute amounts. Vimentin and actin g (or b), identified
by the analysis of protein spots up-regulated following laser
treatment, have an apparent molecular weight higher than the
theoretical one. This phenomenon was also observed for other
proteins identified by the analysis of up-regulated protein
spots. As we can note from Fig. 3 and Table 1, desmin (spot
No. 16), pyruvate kinase isozymes M1/M2 (spot No. 22) and
elongation factor 2 (spot No. 21) show a measured molecular
weight higher than the theoretical one. We hypothesize that MLS
laser treatment could induce the stabilization of pre-existing
covalent polymeric species or their formation.
Classification and functional analysis of modulated proteins
In order to gain insight into the biological significance of the
proteins identified by proteomic analysis, the 42 differentially
expressed proteins, identified by MALDI-Tof peptide mass
finger printing of 52 isolated protein spots, were categorized
according to the DAVID bioinformatics tool. Concerning biological
processes, the identified proteins were distributed into categories;
we report here the results obtained with the PANTHER (Protein
Analysis Through Evolutionary relationships) classification system
(Table 2). The main biological process in which the identified
Fig. 2 Cytoskeleton organization in C2C12 cells after MLS laser treatment. a, b:
actin immunostaining. c, d: tubulin immunostaining. e, f: vimentin immunostain-
ing. In control C2C12 cells (a) actin resulted highly expressed in the perinuclear
area and formed a distinguishable ‘‘actin ring’’ close to the plasma membrane
(arrows). Some stress fibers were present. After a cycle of three laser treatments
(b) the ‘‘actin ring’’ delimiting each individual cell disappeared. The cells tended
to align and fuse to form tubes, filaments running parallel to the axis of the tubes
appeared (arrows), the perinuclear area with high actin expression was thicker. In
control cells (c), microtubules showed a radial distribution starting from the
organization centre close to the nucleus. In treated samples (d) the microtubules
oriented parallel to the major axis of the cells and passed from one cell to another
without interruption (arrows). In control cells (e), the network of intermediate
filaments was more dense in the perinuclear area, where it had the shape of a
ball. In laser treated cells (f), the intermediate filaments were parallel to the
longitudinal axis of the cells (arrows), which appeared elongated and aligned to
form tube-like structures.
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proteins were involved was ‘‘protein metabolism and modifica-
tion’’ (38.1%), followed by ‘‘cell structure and motility’’ (28.6%),
‘‘carbohydrate metabolism’’ (11.9%), and ‘‘induction of apop-
tosis’’ (7.1%). The four tropomyosin isoforms identified and
assigned to the ‘‘cell structure and motility’’ class can be
categorized also in the ‘‘muscle contraction and development’’
class (not shown). Similarly heat shock proteins can be classi-
fied also as ‘‘stress response proteins’’. It is well known that the
main function of the heat shock proteins is to provide thermo-
tolerance and cytoprotection. Hsp-b1, up-regulated after MLS
laser treatment, belongs to the small heat shock protein group.
It is overexpressed during different stages of cell differentiation
and development and it is thought to have an essential role in
the differentiation processes of numerous tissues.44
The membership of most of the identified proteins to the
class ‘‘protein metabolism and modification’’ clearly indicates
a cellular response toward specific anabolic events, probably
related to cytoskeleton network remodelling, leading to the
morphological changes observed and described above. It is also
remarkable that about 30% of the changes shown by proteomic
analysis in laser treated samples concern proteins involved in
cell structure and motility, such as actin g/b, tropomyosin a and
b chains, vimentin, desmin, LIM domain and actin-binding
protein, fascin, cofilin-1, many of which are actin-binding
proteins and/or have been found to have a role in myogenesis.
It has been demonstrated that the LIM domain and actin-
binding protein increases when myoblasts are induced to
differentiate and then progressively declines in myotubes.45,46
Therefore, the increase in the LIM domain and actin-binding
protein we observed fits with a scenario of differentiation at the
early stages. Another interesting identified protein is a-enolase
that results up-regulated after MLS laser treatment. Although it
is clusterized into the class ‘‘carbohydrate metabolism’’, it is
known that a-enolase is also involved in other cellular
processes. It has been recently demonstrated that enolase
isoforms interact with microtubules during muscle satellite
cell differentiation contributing to the regulation of the cyto-
skeletal filaments dynamism that occurs during the transition
from myoblasts to myotubes.47,48 NLR family pyrin domain-
containing protein 10 (NLRP 10), heterogeneous nuclear
ribonucleoprotein K (HNRNP K) and galectin-3 following
the PANTHER classification system were assigned to the
‘‘induction of apoptosis’’ class but they are also involved in
other important processes.
Fig. 3 Representative reference 2-DE gel of C2C12 cells. Cell lysates of control C2C12 cells and MLS-treated C2C12 cells were resolved by 2-DE. IEF was carried out on
nonlinear wide-range IPGs (pH 3–10; 18 cm IPG strips) and achieved using the Ettant IPGphort system. Sample load, 800 mg per strip, was successively performed by
cup loading in the IPGphor Cup Loading Strip Holders. The second dimension was carried out on 9–16% polyacrylamide linear gradient gels (18 cm  20 cm 
1.5 mm). Protein spots were visualized by colloidal coomassie blue staining. 2-DE gels were analysed using the Progenesis SameSpot software package. The arrows
point to differential protein spots identified with the peptide-mass fingerprinting.
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NLRP 10 is one of 14 pyrin domain containing members of
the NOD-like receptor family of cytoplasmic receptors. It is an
intracellular protein involved not only in apoptosis but also in
the immune system function. In fact it is believed that NLRP 10
helps to regulate the inflammatory response. NLRP 10 reduces
inflammatory and innate immune responses by inhibiting the
activity of two proteins associated with the inflammasome:
caspase-1 and PYCARD.49,50 Although the increase in NLRP
10 found after laser treatment does not seem to be connected to
differentiation, it could represent one of the mechanisms
underlying the anti-inflammatory effect attributed to the laser
therapy.
Table 1 Differentially expressed proteins identified by 2-DE coupled to MALDI-Tof MS analysis
MASCOT search results
Spot
no.
Accession
no. Protein names
No. of
matched
peptides
Sequence
coverage Score
Theoretical
pI/Mr (kDa)
Measured
pI/Mr
(kDa)
Fold
increase
ANOVA
(p value)
1 Q02053 Ubiquitin-like modifier-activating enzyme 1 11 16 102 5.43/118.93 5.22/109.33 1.5 0.011
3 Q8K1N2 Pleckstrin homology-like domain family B
member 2
12 9 80 7.58/142.25 6.97/103.90 1.6 0.025
4 P20152 Vimentin 12 32 105 5.06/53.71 4.76/49.61 1.9 0.005
5 P58774 Tropomyosin b chain 11 32 123a 4.66/32.93 4.59/40.20 4.6 0.048
6 P21107 Tropomyosin a-3 chain 13 39 104a 4.68/32.90 4.64/32.85 4.6 0.048
7 Q61598 Rab GDP dissociation inhibitor b 20 46 157 5.93/51.02 5.75/48.36 2.0 0.007
8 O35658 Complement component 1 Q
subcomponent-binding protein
4 28 60 4.82/31.34 4.30/33.18 2.9 0.008
9 Q6IRU2 Tropomyosin a-4 chain 14 50 144 4.65/28.56 4.62/31.86 4.5 0.050
11 P07901 Heat shock protein, HSP 90-a 17 26 82 4.93/85.13 4.91/n.d. 2.9 0.050
12 P11499 Heat shock protein, HSP 90-b 29 43 226 4.97/83.61 4.91/n.d.
13 P20152 Vimentin 26 57 226 5.06/53.71 5.03/105.51 5.7 0.048
14 P20152 Vimentin 26 59 291 5.06/53.71 5.06/106.09 2.5 0.050
15 P20152 Vimentin 7 21 71 5.06/53.71 5.03/81.78 2.5 0.031
16 P31001 Desmin 21 44 195 5.21/53.52 5.22/96.91 1.5 0.033
16 Q91VD9 NADH-ubiquinone oxidoreductase 75 kDa subunit 16 27 129 5.51/80.75 5.21/85.82 1.5 0.033
17 Q6ZWM3 Actin g 10 38 108 5.29/42.05 5.24/67.30 8.1 0.032
P63260 Actin b 10 38 108 5.31/42.11
19 P18760 Cofilin-1 6 57 80 8.22/18.78 n.d./19.93 1.9 0.050
20 Q3TL91 Rho GTPase-activating protein 31 13 12 72 5.58/156.55 6.28/166.41 1.7 0.031
21 P58252 Elongation factor 2 20 42 203 6.41/96.22 6.74/151.03 1.9 0.031
22 Q91YI8 Pyruvate kinase isozymes M1/M2 12 32 138 7.18/58.38 7.17/120.36 3.4 0.022
23 Q9ERG0 LIM domain and actin-binding protein 1 23 27 133 6.18/84.66 6.70/93.27 1.8 0.034
24 P16110 Galectin-3 8 34 110 8.46/27.61 n.d./33.13 3.2 0.042
25 P56399 Ubiquitin specific peptidase 5 7 7 81 4.89/96.68 6.48/96.08 3.2 0.004
26 Q9ERG0 LIM domain and actin-binding protein 1 18 26 119 6.18/84.66 6.36/96.49 4.6 0.049
27 P60843 Eukaryotic initiation factor 4A-I 14 48 191 5.32/46.35 5.38/48.61 1.5 0.015
28 P61979 Heterogeneous nuclear ribonucleoprotein K 10 23 109 5.39/51.23 5.14/59.29 1.5 0.028
29 Q61696 Heat shock protein, HSP 70 12 25 123 5.53/70.32 5.48/69.42 2.6 0.001
30 P62141 PP1-b catalytic subunit 10 36 94 5.84/37.96 5.80/42.44 1.9 0.002
31 P50580 Proliferation-associated protein 2G4 14 51 169 6.41/44.01 6.57/48.61 2.9 0.049
32 Q61553 Fascin 12 34 148 6.44/55.22 6.64/52.38 1.6 0.033
34 P80314 T-complex protein 1 subunit b 15 35 171 5.97/57.78 6.29/55.47 1.5 0.050
35 P26638 Seryl-tRNA synthetase 21 45 239 5.95/58.86 6.37/57.87 1.8 0.005
36 Q62465 Synaptic vesicle membrane protein VAT-1
homolog
6 21 68 5.95/43.30 5.79/50.91 2.4 0.005
37 Q61598 Rab GDP dissociation inhibitor b 9 27 83 5.93/51.02 5.84/48.49 2.1 0.010
38 P14602 Heat shock protein, HSP b-1 10 50 122 6.12/23.06 6.08/27.93 4.1 0.004
39 P58771 Tropomyosin a-1 chain 15 45 165 4.69/32.72 4.75/32.39 3.5 0.049
40 P21107 Tropomyosin a-3 chain 9 21 157a 4.68/32.90 4.68/31.75 5.8 0.029
41 P17742 Peptidyl-prolyl cis–trans isomerase A 6 42 107 7.74/18.13 n.d./17.35 8.6 0.022
42 Q9JIG7 Coiled-coil domain-containing protein 22 9 18 71 5.71/71.26 5.00/67.81 1.8 0.016
Q6ZWM3 Actin g 8 26 73 5.29/42.05 5.58/46.10 2.3 0.008
44 P63260 Actin b 8 26 73 5.31/42.11
46 Q61990 Poly(rC)-binding protein 2 7 28 81 6.33/38.60 6.66/43.85 1.5 0.023
51 P43025 Tetranectin 5 24 74 5.50/22.64 6.27/26.31 3.1 0.007
53 Q8CCN1 NLR family, pyrin domain-containing protein 10 21 29 159 6.18/72.29 5.79/87.84 3.1 0.008
54 O08553 Dihydropyrimidinase-related protein 2 14 37 172 5.95/62.64 6.42/65.412 1.8 0.050
55 Q9CWJ9 Bifunctional purine biosynthesis protein 12 35 174 6.30/64.69 6.64/66.09 1.6 0.034
56 P06151 L-Lactate dehydrogenase A chain 13 34 131 7.62/36.82 7.36/36.55 2.4 0.033
58 Q8R4K2 Interleukin-1 receptor-associated kinase 4 9 25 100 5.23/51.41 5.78/83.51 5.2 0.012
59 P58252 Elongation factor 2 8 12 70 6.41/96.22 6.15/78.39 2.9 0.050
60 P17182 a-Enolase 13 45 153 6.37/47.45 6.28/49.47 4.4 0.031
61 P17182 a-Enolase 17 55 212 6.37/47.45 6.41/49.22 1.5 0.023
a The number of accepted missed cleavage sites was set to two.
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HNRNP K belongs to the subfamily of heterogeneous
nuclear ribonucleoproteins (hnRNPs). These proteins are
associated with pre-mRNAs in cell nucleus and are known to
influence pre-mRNA processing and other aspects of mRNA
metabolism and transport. Experiments on animal models
showed that HNRNP K is required for axonogenesis during
development and several of its RNA targets are under strong
post-transcriptional control during the regeneration process.51
The increase in HNRNP K observed in laser treated cells could
be an intriguing starting point for future research, since it has
been shown that IR laser therapy promotes the regeneration of
nerve fibers.52 HNRNP K is also thought to have a role in cell
cycle progression,53 therefore the increase in expression could
also be connected with the beginning of a differentiation
process.
Galectin-3 plays a key role in several intracellular and
extracellular processes. Documented intracellular functions
are the regulation of cell growth, apoptosis and cell cycle.54
Extracellular function consists in mediating/modulating cell
to extracellular matrix adhesive interactions. Recent studies
indicate galectin-3 as a mediator of signal transduction events
on the cell surface as well as a mediator of a variety of extra-
cellular processes such as angiogenesis, neuronal functions,
endocytosis and possibly exocytosis.55
Finally, we would like to highlight the identification of PP1
as one of the up-regulated proteins in MLS laser treated cells.
Interestingly the PP1 catalytic subunit protein is included in
each of the three main classes. PP1 is a major eukaryotic protein
serine/threonine phosphatase that regulates an enormous variety of
cellular functions through specific associations with regulatory
subunits. PP1, primarily known for its role in the carbohydrate
metabolism, actually regulates functions such as actin and
actomyosin reorganization, cell shape and cell adhesion, muscle
contraction/relaxation.56
To assess the identity of PP1 we performed an
immunoblot analysis using a specific anti-PP1 antibody. Actin
and enolase were selected to undergo a confirmatory test as
well. Fig. 5 shows immunoblot results in comparison with
the colloidal coomassie staining. Western blot analysis also
confirms the up-regulation of enolase and the up-regulation
of PP1 in laser treated cells, according to 2-DE gel image
analysis.
Another interesting aspect highlighted by the DAVID classi-
fication system as a function of the keywords is that 81% of the
identified proteins are classified as ‘‘phosphoproteins’’
(Table 3). Some of these proteins actually are PP1 substrates
or interact with it (i.e. cofilin,57 heterogeneous nuclear ribo-
nucleoprotein K,58 enolase,59 heat shock proteins,60,61 peptidyl-
prolyl isomerase,62 vimentin63,64).
The overexpression of cofilin is notable. Cofilin is a protein
associated with the cytoskeleton that binds actin and reversibly
controls polymerization and depolymerization in a pH-sensitive
manner; the ability of cofilin to control actin polymerization is
known to be regulated by reversible phosphorylation.65 Cofilin
is phosphorylated by LIM kinase 1, which abolishes its ability to
de-polymerize actin, and dephosphorylated by PP1 and PP2A.66
PP1 and PP2A play an important role in myoblast differentia-
tion. It has been shown that inhibition of PP1 and PP2A by
okadaic acid blocks myogenesis by altering the MyoD binding
activity67 and depletion of PP1 abolishes the ability of myoblasts
to differentiate into myotubes.68 Proteomic analysis of samples
exposed to MLS laser treatments for 3 consecutive days showed
an increase in PP1 but no significant changes in PP2A. This
finding completely agrees with the results of other authors, who
examined PP1 and PP2A activities during various stages of
myogenesis in rat skeletal muscle cells. PP1 activity increased
progressively in cultures from 2 to 5 days, PP2A activities
remained constant in days 2–4 cultures and increased sharply
on day 5.69 An indirect proof of the key role played by PP1 in
muscle homeostasis is the decrease of PP1 levels, associated with
a decrease in metabolic enzymes, observed in hypotrophic and
sarcopenic muscles.70
Finally it is also relevant that 28.7% of the identified
proteins are ‘‘ATP-binding proteins’’, 19% are ‘‘coiled coil
proteins’’ and 16.7% ‘‘actin-binding proteins’’. The increased
availability of ATP induced by exposure to the red-IR laser
radiation71 could be correlated with the net increase of proteins
capable of binding ATP. Changes in the expression of actin-
binding proteins, as well as those in typical intermediate
filament proteins (here classified in part as ‘‘coiled coil’’
proteins), are events related to the general cytoskeletal rearran-
gement also observed by fluorescence microscopy (Fig. 2).
Fig. 4 Protein shift position of actin g (or b), vimentin, tropomyosin a-3 chain,
and Rab GDP dissociation inhibitor b upon MLS-treatment of C2C12 cells. The
panels show the regions, selected by representative 2-DE gels, with actin g (or b),
vimentin, tropomyosin a-3 chain, and Rab GDP dissociation inhibitor b localiza-
tion. The indicated proteins shift their position in response to MLS-treatment due,
likely, to post-translational modification.
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MLS laser treatment induces a significative PPPs activity
increase
The identification of PP1 as one of the up-regulated proteins in
response toMLS laser treatment and the observation that 81% of the
identified proteins are proteins whose function depends on the
phosphorylation status led us to investigate whether there were
changes in the total cellular protein serine/threonine phosphatases
activity. PPPs activity assays, performed on cell lysates obtained after
MLS laser treatment of C2C12 cells, show a 1.8 fold increase with
respect to untreated cells (Fig. 6) confirming the importance of
specific phosphorylation/dephosphorylation events in maintaining
the integrity of intermediate filaments63–65,72 and other fundamental
biological functions.73–76 Fig. 6 shows the results obtained for other
enzymes: lactate dehydrogenase, enolase and pyruvate kinase. All
these proteins are overexpressed after MLS laser treatment and show
an increase in their enzymatic activity.
Table 2 Predominant biological processes associated with LMS-treatment when compared to control C2C12 cells as provided by DAVID (Database for Annotation,
Visualization and Integrated Discovery; http://david.abcc.ncifcrf.gov), using the PANTHER classification system. m: up-regulated proteins; k: down-regulated proteins;
k/m: proteins identified from multiple protein spots (both up-regulated and down-regulated). The italicized proteins are present in more than one functional class
Protein metabolism,
modification 38.1%
Cell structure and
motility 28.6%
Carbohydrate
metabolism 11.9%
Induction of
apoptosis 7.1% Not classified 19%
T-complex protein 1
subunit b
m LIM domain and
actin-binding protein 1
m Pyruvate kinase m NLR family, pyrin
domain-containing
protein 10
m Bifunctional purine
biosynthesis protein
m
Heterogeneous nuclear
ribonucleoprotein K
m Cofilin-1 m L-Lactate
dehydrogenase
m Heterogeneous nuclear
ribonucleoprotein K
m Dihydropyrimidinase-
related protein 2
m
Interleukin-1 receptor-
associated kinase 4
m Desmin m PP1-b m Galectin-3 m NADH-ubiquinone
oxidoreductase
m
Eukaryotic initiation
factor 4 A-I
m Fascin m Synaptic vesicle
membrane protein
VAT-1
m Rab GDP dissociation
inhibitor b
m
Peptidyl-prolyl cis–trans
isomerase A
m Tropomyosin a-1 m a-Enolase m Rho GTPase-activating
protein 31
m
Proliferation-associated
protein 2G4
m PP1-b m Coiled-coil domain-containing
protein 22
k
Seryl-tRNA synthetase m Tropomyosin b k Pleckstrin homology-like
domain family B member 2
k
Ubiquitin specific
peptidase 5
m Tropomyosin a-4 k Complement component
1 Q subcomponent-binding
protein
k
HSP 90-a m Vimentin k/m
HSP 90-b m Actin g k/m
HSP b-1 m Actin b k/m
HSP 70 m Tropomyosin a-3 k/m
PP1-b m
Elongation factor 2 m
Poly(rC)-binding protein 2 k
Ubiquitin-like modifier-
activating enzyme 1
k
Fig. 5 Validation of the PP1 identity by immunoblot analysis. 100 mg of protein extracts from control and MLS treated C2C12 cells were separated by 2-DE and
transferred on a PVDF membrane. The blots were incubated with anti-PP1 antibody. Anti-actin and anti-enolase antibodies were used as loading and position control.
Blots were visualized by autoradiography (c, d). The panels represent the 2-DE selected regions in which localize PP1, actin and enolase. The upper panels (a, b) show
the colloidal coomassie blue stained gels.
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Experimental
Cell culture
Murine myoblasts (C2C12 skeletal muscle cell line) were routinely
cultured in growing medium consisting of Dulbecco’s Modified
Eagle’s Medium supplemented with 100 mg ml1 streptomycin,
100 U ml1 penicillin, 2 mM glutamine and 10% fetal bovine
serum (FBS). Cells were incubated at 37 1C and 5% CO2. All the
reagents for cell culture were purchased from Sigma Chemical Co.
(St Louis, MO, USA).
MLS laser treatment
The treatments have been performed with a Multiwave Locked
System (MLS) laser (ASA Srl, Vicenza, Italy), a device already
used for some years in clinics (FDA approved and CE certified
instrument) and specifically applied in physical medicine and
pain therapy. It is a high power (average power up to 1.1 W,
class IV) IR laser with two synchronized sources (laser diodes).
The two modules have different wavelengths, peak power and
emission mode. The first one is a pulsed laser diode, emitting
at 905 nm, with a peak optical power = 25 W; each pulse is
composed of a pulse train (single pulse width = 100 ns,
maximum frequency 90 kHz), thus varying the average power
delivered to the tissue. The frequency of the pulse trains may be
varied in the range 1–2000 Hz. The second laser diode (808 nm)
operates in continuous mode (power 1.1 W) or in pulsed mode
(pulses repetition rate 1–2000 Hz), mean optical power output =
550 mW, duty ratio 50% independent of the pulse repetition
rate. The two propagation axes are coincident.
For the treatment, cells were seeded in the central 8 wells of
a 24-multiwall plate. The plate was placed inside a plexiglass
support, specifically designed and built. On the top of the
support there was a central groove in which the laser handpiece
slided. The plate was perfectly aligned with the handpiece, at a
distance of 3 cm from it, so that the spot formed by the two
superimposed laser beams had a diameter equal to that of a
single well (13 mm). The support allowed us to perform a
homogeneous scan of 8 samples at the same time, by moving
the spot at a constant horizontal velocity above the 8 treated wells
(5.6 cm s1: each scan of 8 wells lasted 20 s), in order to have the
same radiant energy impinging into each well (B68 J for the whole
treatment). Treatment parameters were 1500 Hz frequency and
8 min total scan time. The scan mode is also extensively used in
clinics because it allows us to treat easily larger areas and, together
with the other treatment parameters chosen, contributes to achieve
the desired effects avoiding any side effects.
The treatment was repeated once a day, for 3 consecutive
days under sterile conditions. The treated samples were com-
pared with controls maintained under the same conditions,
except for the laser exposure.
Viability and proliferation
Cell viability was assessed by the Trypan Blue assay after a
single exposure and 3 exposures (once a day for 3 consecutive
days) to MLS treatment. The treated samples were compared to
untreated controls. After the MLS treatment, the samples were
washed and cell detachment was obtained by treating with
trypsin–EDTA for 3–4 minutes. Then the cells were centrifuged and
resuspended in a solution of phosphate buffered saline (PBS) and
Trypan Blue (dilution factor: 2). The dye is able to penetrate
selectively into dead cells. After 5 min of incubation, cell counts
were performed by using a Neubauer haemocytometer.
Immunofluorescence analysis
At the end of the experiments, cells were fixed for 5 min in cold
acetone, then washed in phosphate buffered saline (PBS). After
blocking unspecific binding with PBS containing 3% bovine
serum albumin, cells were incubated overnight at 4 1C with
the specific anti-MyoD (Santa Cruz Biotechnology, SC-32758),
anti-a-actin (Millipore, MAB1501X), anti-tubulin (Upstate Bio-
technology, 05829) and anti-vimentin (Chemicon, MAB1681)
antibodies. The cells were then incubated with the fluorescein
isothiocyanate (FITC) conjugated specific secondary antibodies
(specifically: anti-mouse IgG (Chemicon Int, AP 124-T) for anti-
tubulin antibody and anti-mouse IgM (Chemicon Int, AP 132-T)
for anti-vimentin antibody). Cells incubated with anti-a actin
antibody did not need incubation with the secondary antibody
since a mouse anti-actin Alexa Fluors 488 conjugated was used.
Negative controls were obtained by omitting the primary anti-
bodies. Samples were evaluated using an epifluorescence
microscope (Nikon, Florence, Italy) at 100 magnification
and imaged by a HiRes IV digital CCD camera (DTA, Pisa, Italy).
Image analysis was performed by extracting, for each cell
image, the region of interest (ROI) by appropriate software
(Image Pro Plus). Then, the mean pixel value (16 bit, gray level)
related to the mean fluorescence intensity and therefore to the
specific epitope detection was calculated.
Data analysis
Three different experiments were carried out in triplicate. For
viability and proliferation assays at least 10 counts per sample
were carried out and the mean value was calculated.
Fig. 6 Enzymatic assays of some overexpressed proteins and cellular protein
phosphatases. The enzymatic activity of protein serine/threonine phosphatases
(PPPs), lactate dehydrogenase (LDH), enolase, and pyruvate kinase (PK) was
determined in cell lysates by specific tests. The figure shows the activity fold
increase observed in MLS-treated C2C12 cells with respect to control cells. Results
shown represent means of two experiments in duplicate (SEM (*p r 0.05)).
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For immunofluorescence analysis, at least 30 cells per slide
were scored in 10 random fields per slide, and the data were
expressed as mean  SD. Statistical significance was deter-
mined using a Student’s t-test. A p value lower than 0.05 was
considered statistically significant.
Proteomic sample preparation and 2-DE
For 2-DE, MLS treated and control cells were harvested by
centrifugation at room temperature. The pellet was washed
twice in water and resuspended in 8 M urea, 4% CHAPS, and
10 mM DTT. After sonicating briefly, protein extracts were
clarified by centrifugation at 14 000  g for 10 min. The protein
concentration of each purified sample was determined using
the 2D Quant kit (GE Healthcare, USA). For each experimental
condition 2-DE replicate gels (n = 3) were made using independent
experiments, in order to assess biological and analytical variations.
IEF (first dimension) was carried out on nonlinear wide-range IPGs
(pH 3–10; 18 cm long IPG strips; GE Healthcare, Uppsala, Sweden)
and achieved using the Ettant IPGphort system (GE Healthcare).
IPG-strips were rehydrated with 350 ml of lysis buffer and 2% v/v
carrier ampholyte, for 12 h at room temperature. Sample load,
800 mg per strip, was successively performed by cup loading in the
IPGphor Cup Loading Strip Holders (GE Healthcare), with the
sample cup system at the anodic side of IPG strips. IEF was then
achieved according to the following voltage steps, at 20 1C: 30 V for
30 min, 200 V for 2 h, 500 V for 2 h, from 500 to 3500 V for 30 min,
3500 V for 5 h, from 3500 to 5000 V for 30min, 5000 V for 4 h, from
5000 to 8000 V for 30 min, 8000 V until a total of 95000 V h1 was
reached. After focusing, prior to the second-dimension separation,
IPG strips were equilibrated in equilibration buffer (6 M urea,
75 mM Tris–HCl pH 8.8, 29.3% glycerol, 2% SDS) containing
1% (w/v) DTT for 15 min and then in the same equilibration buffer
containing 2.5% iodoacetamide for a further 15 min.
The second dimension separation was carried out on 9–16%
polyacrylamide linear gradient gels (18 cm  20 cm  1.5 mm)
at 40 mA per gel constant current and 10 1C until the dye front
reached the bottom of the gel.77 Protein spots were visualized
by colloidal coomassie blue staining.78 The stained gels were
scanned with the Epson Expression 1680 Pro image scanner.
Image analysis
Scanned images (16-bit grayscale) were processed and statisti-
cally evaluated with Progenesis SameSpots software (Nonlinear
Dynamics, Newcastle upon Tyne, UK). Both manual and auto-
matic alignment was used to align the images. A control group
and a ‘‘laser treated’’ group containing three technical repli-
cates were created and only spots present in all the replicates
were taken into consideration for subsequent analysis. The two
groups were compared with each other and fold values as well
as p-values of all spots were computed by the above-mentioned
software using one way ANOVA analysis. All spots were prefil-
tered and manually checked before applying the statistical
criteria (Anova p r 0.05 and fold Z 1.5). Normalized spot
volumes, instead of spot intensity, were used in statistical
processing. Protein identification involved only spots that
fulfilled the statistical criteria. Experimental pI and Mw values
were estimated using MW protein markers and some identified
proteins selected as markers.
In-gel digestion and MALDI-TOF analysis
Protein spots were manually excised from gels and each sample
was transferred to a 1.5 ml Eppendorf tube, washed twice in
50 mM ammonium bicarbonate (NH4HCO3)/CH3CN 1/1 for
15 min and then de-hydrated in CH3CN. Dried samples
were re-swelled in NH4HCO3 containing 10 mM DTT (freshly
prepared) and incubated for 30 min at 56 1C; the excess liquid
was then removed and replaced with the same volume of
freshly prepared 55 mM IAA in 25 mM NH4HCO3. After
30 min of incubation at room temperature in the dark, the
gel particles were washed twice with NH4HCO3/CH3CN 1/1 for
15 min, de-hydrated in CH3CN and dried in a vacuum centri-
fuge. Each sample was incubated for 1 h at 37 1C in 20 ml of
20 mg ml1 trypsin solution (Trypsin Proteomics Sequencing
Grade T6567, SIGMA) in 40 mM NH4HCO3 with 10% CH3CN.
An additional 30 ml of 40 mM NH4HCO3 with 10% CH3CN were
added to each sample and incubated overnight at 37 1C. The
reaction was stopped by adding a final concentration of 0.1%
trifluoroacetic acid. The supernatant was collected and the gel
was further extracted with 0.1% trifluoroacetic acid in 50%
CH3CN.
79,80 The extracts were combined and then analysed on
a MALDI-TOF/TOF mass spectrometer Ultraflex III (Bruker
Daltonics, Bremen, Germany) by using Flex Control 3.0 as data
acquisition software. A 0.75 ml volume of the sample was mixed
with 0.75 ml of the matrix (saturated solution of a-cyano-4-
hydroxycinnamic acid in 50% (v/v) CH3CN and 0.5% (v/v) TFA)
on the anchorchip target plate and allowed to dry. Spectra were
acquired in the reflectron mode over them/z range 860–4000 for
a total of 500 shots. The instrumental parameters were chosen
by setting the ion source 1 at 25 kV, ion source 2 at 21.5 kV,
the pulsed ion extraction at 20 ns and the detector gain at 7.7.
The instrument was externally calibrated prior to analysis
using the Bruker Peptide Calibration standard kit. All the
resulting mass lists were cleaned up from eventually present
contaminant masses, such as those from matrix, autodigestion
of trypsin and keratins. Mass fingerprinting searching was
carried out in Swiss-Prot/TrEMBL databases using MASCOT
(Matrix Science Ltd., London, UK, http://www.matrixscience.com)
software. The taxonomy was restricted to Mus musculus, a mass
tolerance of 50 ppm was allowed, and the number of accepted
missed cleavage sites was set to one. Alkylation of cysteine by
carbamidomethylation was assumed as fixed modification. The
experimental mass values were monoisotopic. No restrictions
on protein molecular weight and pI were applied. The criteria
used to accept identifications included the extent of sequence
coverage, number of matched peptides and probabilistic score
sorted by the software.
Western blot
Western blot analysis was performed to validate the identity
and the differential expression of PP1, enolase and actin. 100 mg
of protein extracts from control and MLS treated C2C12 cells
were separated by 2-DE as previously described and transferred
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onto a PVDF membrane (Millipore). The blots were incubated
with anti-actin (Santa Cruz Biotechnology, SC-1615), anti-
enolase (Santa Cruz Biotechnology, SC-7455) and anti-PP1
antibodies (Santa Cruz Biotechnology, SC-7482) in blocking
buffer (PBS, 2% nonfat dry milk, 0.1% v/v Tween-20). After
incubation with secondary antibodies, the blotting was devel-
oped by using the ECL plus immunodetection system ECL (GE
Healthcare) and visualized by autoradiography.
Cluster analysis
The differentially expressed proteins were subjected to func-
tional pathway analysis using DAVID database (http://david.
abcc.ncifcrf.gov/home.jsp)81 for better understanding of the
biological context of the identified proteins and their participa-
tion in various physiological processes. UniProt accession
numbers of the 42 differentially expressed proteins identified
in our study were uploaded and mapped against the Mus
musculus reference dataset to extract and summarize functional
annotation associated with individual or group of genes/proteins
and to identify gene ontology terms, molecular function, biological
process and important pathways for each dataset.
Determination of protein serine phosphatases, pyruvate kinase,
enolase and lactate dehydrogenase activities
Protein Serine Phosphatases (PPPs) activity was determined
in C2C12 cell lysates from three independent experiments.
MLS-treated and not treated C2C12 cells were quickly rinsed
in ice-cold phosphate-buffered saline (PBS, 10 mM sodium
phosphate and 0.15 M NaCl, pH 7.2), and freezed. After thawing
the material at room temperature, the lysis was performed at
4 1C in 50 mM Tris, pH 7.4, containing 5 mM dithiothreitol and
Sigma protease inhibitors mix (1/100, v/v). After 30 min of
incubation on ice, lysates were sonicated (three short bursts)
and centrifuged at 12 000g in a microcentrifuge at 4 1C for
30 min. Supernatants were quantified with respect to proteins
content by the Bradford method. PPPs activity was determined
using p-nitrophenyl phosphate as the substrate. All enzymatic
activity tests were performed in duplicate. The substrate (4 mM)
was dissolved in 25 mM Tris–HCl buffer, pH 7.2, containing
5 mM dithiothreitol, 20 mM sodium–potassium DL-tartrate and
0.1 mM sodium orthovanadate. Tartrate and orthovanadate
were added in order to inhibit protein tyrosine phosphatases,
lysosomal acid phosphatases and non-specific phosphatases.82,83
The reaction was stopped with 0.1 M KOH and the released
p-nitrophenolate ion was measured by reading the absorbance at
400 nm (e = 18000 Ml cm1). The activity measured under these
conditions was completely inhibited by 0.01 mM cantharidic acid,
a specific and strong inhibitor of all PPPs.84 Statistical significance
was determined using a Student’s t-test. A p value lower than
0.05 was considered statistically significant.
Pyruvate kinase (PK) activity was determined at 30 1C
according to Bergmeyer,85 with slight modifications, continuously
following the NADH oxidation at 340 nm, using an UV-2100
spectrophotometer (Shimadzu, Columbia, MD). The assay mix-
ture contained in 1 ml final volume consisted of 50 mM
triethanolamine (pH 7.6), 8 mM MgSO4, 5 mM EDTA, 75 mM
KCl, 1.5 mM ADP, 0.15 mM NADH, 60 units of lactate dehydro-
genase. The reaction was started by adding substrate (0.8 mM
phosphoenolpyruvate). Enolase activity was determined at 30 1C
according to Bergmeyer,86 with slight modifications, continuously
following the NADH oxidation at 340 nm, using an UV-2100
spectrophotometer (Shimadzu, Columbia, MD). The assay mixture
contained in 1ml final volume consisted of 80mM triethanolamine
(pH 7.6), 3.3 mM MgSO4, 1.1 mM ADP, 0.2 mM NADH, 20 units of
lactate dehydrogenase, 3 units of pyruvate kinase. The reaction was
started by adding substrate (0.9 mM phosphoglycerate). Lactate
dehydrogenase (LDH) activity was determined at 30 1C according to
Bergmeyer,87 with slight modifications, continuously following the
decrease of NADH at 340 nm, using an UV-2100 spectrophotometer
(Shimadzu, Columbia, MD). The assay mixture, contained in 1 ml
final volume, consisted of 100 mM phosphate buffer pH 7.0 and
0.2 mM NADH. The reaction was started by adding substrate
(0.77 mM pyruvate). The value of 6.22 mM1 cm1 is considered
to be the NADH molar extinction coefficient. One unit of activity is
defined as that quantity of enzyme which transforms one mmole of
substrate in one minute at 30 1C.
Conclusions
The aim of this study was to investigate the response of
myoblasts to IR laser treatment in order to get further insights
into the cellular and molecular mechanisms underlying the
effects of laser therapy on muscle tissue described in clinical
studies and on animal models. Our results show that laser
treatment, with the source and parameters chosen, did not
affect cell viability but induced a decrease in cell proliferation
and increase in expression of the early differentiation marker
MyoD, associated with changes of cell morphology and cytoskeletal
architecture leading to the formation of tube-like structures. Taken
together, these findings suggest that the exposure to IR laser
triggers a differentiation process in myoblasts.
The analysis of differential expression in the proteomic
profile of laser treated and untreated cells, which to the best
of our knowledge had never been performed before, further
confirmed in treated cells a scenario of differentiation process
in its early stages. In fact, following laser exposure, numerous
proteins known to be involved in cell cycle regulation, cytoskeleton
organization and differentiation showed a significant increase or
modulation. The fact that IR laser treatment seems to be able to
promote myoblast differentiation in vitro could in part explain the
regenerative and reparative effects attributed to laser therapy when
applied tomuscle injury in clinics. Very interestingly, the proteomic
analysis also revealed the increase of numerous ATP-binding
proteins and proteins involved in the regulation of muscle
metabolism, as PP1, establishing a connection with the
well-known effect of red-IR laser radiation on the activity of
cytochrome oxidase and ATP synthesis.4 Moreover, among the
proteins overexpressed in the treated cells there were NLRP
10 and other proteins which regulate the inflammatory response
and could contribute to the anti-inflammatory action attributed
to laser therapy. Finally, the increase of proteins involved in cell
adhesion/migration, angiogenesis and axonogenesis fits with the
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possibility to induce by laser treatment mechanisms related to
tissue repair processes.
In conclusion, this study reports for the first time a proteo-
mic analysis of IR laser treated myoblasts, thus contributing
with original results to shed light on molecular and cellular
mechanisms underlying the effect of laser therapy in muscle
repair and recovery.
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